hepatitis

View All

Pharma News for Actinium, Santhera, Gilead, Seres, BMS, Boehringer
Actinium Announces SIERRA Trial Results; Santhera Seeks FDA Review for Vamorolone; Seres Announces BLA Submission for SER-109; BMS Announces Results of COMMANDS Trial; Boehringer’s PDE4B Moves Late-stage Clinical Testing; FDA Rejects Gilead’s Hepcludex; Approval to J&J’s BCMAxCD3 Bispecific Antibody for Multiple Myeloma; Syncona to Acquire AGTC

Actinium Announces Positive Top-line Results from Pivotal Phase III SIERRA Trial of Iomab-B Actinium Pharma is on track to submit its targeted radiotherapy for AML patients requiring a bone marrow transplant in the United States, boosted by top-line data from a pivotal trial. The SIERRA trial of Iomab-B, an anti...

Find More

Latest Pharma News for VistaGen and Merck
VistaGen’s PH94B for Anxiety Disorder; Keytruda for Head and Neck Cancer Treatment; Bavarian Nordic’s Smallpox Vaccine Imvanex; CAMP4 Raises USD 100 Million; Incyte’s WU-CART-007; Incyte’s Opzelura for Vitiligo; AstraZeneca and Merck’s Lynparza; Sumitomo Pharma’s DSP-0390 for Brain Cancer

FDA Approves Incyte’s Opzelura as First Vitiligo Therapy The US Food and Drug Administration has approved Incyte’s Opzelura cream 1.5% for the topical treatment of non-segmental vitiligo in adult and paediatric patients 12 years of age and older. With this approval, Opzelura is the first and only FDA-approved...

Find More

Hepatitis D Market | Hepatitis D Treatment Market | HDV Market
Increasing Prevalence and Upcoming Novel Therapeutic Approaches: What is Shaping the Hepatitis D Market Outlook?

Recent years have been experiencing a dramatic increase in the number of Hepatitis D cases. It is spreading at a rapid rate. DelveInsight estimated that the total diagnosed Hepatitis D prevalence was reported to be 204,976 in 2017 in the 7MM (the US, EU5 (the UK, Germany, Spain, France, and Italy) and Japan). Furth...

Find More

Chronic Hepatitis B Market
Search for the Cure Continues in the Chronic Hepatitis B Treatment Market

Hepatitis B virus (HBV) infection is the 10th leading cause of death worldwide. With 2 billion people infected all over, HBV infection is a reason behind 500 000 to 1.2 million deaths per year. Hepatitis B is a lethal infection and has been a major global problem for years. If it lasts for over 6 months, it is term...

Find More

Hepatitis B and C Treatment and Upcoming Therapies
Evolution in Hepatitis B and C Virus: Can we expect success similar to Hepatitis C in Hepatitis B as well?

Hepatitis is an infection that causes inflammation of the liver. The condition can be self-limiting or can progress to fibrosis (scarring), cirrhosis, or liver cancer. Hepatitis viruses are the most common cause of hepatitis; however, other infections such as toxic substances (e.g., alcohol, certain drugs) and auto...

Find More

Hepatitis
World Hepatitis Day

World Hepatitis Day is observed on 28 July of every year, aims to bring the world together to raise the awareness of the global burden of viral hepatitis and bring real change. Hepatitis B virus is a blood-borne and transmitted sexually by the virus, which is acquired by percutaneous and exposure to blood or ot...

Find More

Hepatitis C drugs re-energize global fight over patents

The liver disease hepatitis C is the new battleground for lawsuits intended to slash the cost of life-saving medicines. In February alone, five suits were filed in India and Argentina claiming that the latest class of antiviral drugs does not warrant the 20-year patent monopoly that manufacturers have sought in thos...

Find More

Delveinsight
Small interfering RNA (siRNA) Therapeutics

In the years since the discovery of RNA interference, researchers have found that this process is far more widespread than we might expect, and that small pieces of RNA play many functional roles. Small (or short) interfering RNA (siRNA) is the most commonly used RNA interference (RNAi) tool for inducing short-term ...

Find More